Cyproheptadine and COVID-19: A Discussion with Dr. Farid Jalali

In an important webinar series sponsored by Steve Kirsch and his COVID-19 Early Treatment Fund (CETF), Farid Jalali presents COVID-19: Serotonin Dysregulation Cause of Pulmonary Vasoregulatory Dysfunction Contributor to Morbidity and Death.  In this presentation Farid Jalali discusses Cyproheptadine, an anti-histamine,   and its potential use targeting COVID-19.  Dr. Jalali shares that based on numerous studies now COVID-19 risks associated with heightened platelet activation representing higher intensity than with other forms of disease escalation such as acute  respiratory distress syndrome (ARDS) and sepsis. The doctor argues that elevated serotonin associated with COVID19 is reversible via Cyproheptadine  for acute illness.  With ongoing studies, some real world data the presenters suggest the potential for Cyproheptadine for select COVID-19 cases.  Watch this fascinating video to learn more.

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee